相关实验视频
Updated: Jun 27, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.4K
帕金森病的长期药物治疗概况在亚thalamic深度大脑刺激下:一项受控研究
Christoph Theyer1, Vincent Beliveau1, Florian Krismer1
1Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
Movement disorders clinical practice
|May 8, 2024
概括
脑下深层刺激 (STN-DBS) 显著减少了帕金森病 (PD) 患者在14年内需要的药物. 与未经手术治疗的对照组相比,STN-DBS患者需要更少的药物治疗.
科学领域:
- 神经学 神经学
- 神经外科 神经外科
- 运动障碍 运动障碍
背景情况:
- 脑下深层大脑刺激 (STN-DBS) 用于管理帕金森病 (PD).
- 众所周知,STN-DBS可以减少术后对抗帕金森症的药物需求.
- 关于这种药物减少效应的纵向和比较数据有限.
研究的目的:
- 为了比较STN-DBS治疗的PD患者与非手术治疗的对照患者的药物使用轨迹.
- 分析STN-DBS对抗帕金森症药物需求的长期影响.
主要方法:
- 对抗帕金森症药物数据的回顾性分析.
- 该研究包括接受STN-DBS (1999-2010) 和匹配对照的PD患者.
- 对照组是根据发病时的年龄,基线特征,性别分布和并发症来选择的.
主要成果:
- 在74名STN-DBS患者的乐伏多巴相当剂量 (LEDD) 从基线下降了33.9-56.0%,超过14年.
- 61名对照患者的LEDD在大约10年内增加,显示出显著的群体差异.
- 多巴胺激动剂在两组之间的药物类别中表现出最显著的差异.
结论:
- 慢性STN-DBS与PD患者持续较低的LEDD有关,与14年内的对照组相比.
- STN-DBS有助于长期减少抗帕金森症药物需求.
更多相关视频
07:14A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
Published on: May 31, 2016
14.7K
14:14Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
Published on: August 12, 2018
8.9K
相关概念视频
Parkinson's Disease: Treatment
263
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263
Parkinson's Disease: Overview
533
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
533
Drug Therapy
42
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
42